Shasun Swiss Unit Buys Global Rights To ScolrPharma's Nuprin
This article was originally published in PharmAsia News
Executive Summary
Shasun Pharmaceuticals said it Swiss unit, SVADS Holdings, has licensed global rights to develop and market ScolrPharma's Nuprin (ibuprofen) over-the-counter analgesic.